Filing Details

Accession Number:
0001567619-20-018010
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-20 16:59:25
Reporting Period:
2020-10-20
Accepted Time:
2020-10-20 16:59:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1799448 Aligos Therapeutics Inc. ALGS () 1231
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1618788 Vivo Capital Fund Viii, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
1618789 Vivo Capital Viii, Llc C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
1628048 Vivo Capital Surplus Fund Viii, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-20 1,885,611 $0.00 1,885,611 No 4 C Indirect Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 523,726 $0.00 2,409,337 No 4 C Indirect Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 224,054 $0.00 2,633,391 No 4 C Indirect Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 260,380 $0.00 260,380 No 4 C Indirect Vivo Capital Surplus Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 72,320 $0.00 332,700 No 4 C Indirect Vivo Capital Surplus Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 30,939 $0.00 363,639 No 4 C Indirect Vivo Capital Surplus Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 483,267 $15.00 3,116,658 No 4 P Indirect Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2020-10-20 66,733 $15.00 430,372 No 4 P Indirect Vivo Capital Surplus Fund VIII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect Vivo Capital Fund VIII, L.P.
No 4 C Indirect Vivo Capital Fund VIII, L.P.
No 4 C Indirect Vivo Capital Fund VIII, L.P.
No 4 C Indirect Vivo Capital Surplus Fund VIII, L.P.
No 4 C Indirect Vivo Capital Surplus Fund VIII, L.P.
No 4 C Indirect Vivo Capital Surplus Fund VIII, L.P.
No 4 P Indirect Vivo Capital Fund VIII, L.P.
No 4 P Indirect Vivo Capital Surplus Fund VIII, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2020-10-20 1,885,611 $0.00 1,885,611 $0.00
Common Stock Series A Preferred Stock Disposition 2020-10-20 260,380 $0.00 260,380 $0.00
Common Stock Series B-1 Preferred Stock Disposition 2020-10-20 523,726 $0.00 523,726 $0.00
Common Stock Series B-1 Preferred Stock Disposition 2020-10-20 72,320 $0.00 72,320 $0.00
Common Stock Series B-2 Preferred Stock Disposition 2020-10-20 224,054 $0.00 224,054 $0.00
Common Stock Series B-2 Preferred Stock Disposition 2020-10-20 30,939 $0.00 30,939 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
  2. Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.